E1105 Nontarget Lesions Supplemental Form (RECIST) NCT00520975 First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Source Form: NCI FormBuilder:

  1. 8/26/12 8/26/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 6/8/15 6/8/15 -
Uploaded on:

June 8, 2015

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

E1105 Nontarget Lesions Supplemental Form (RECIST) NCT00520975

INSTRUCTIONS: Complete this form only if more than 10 nontarget lesions were present at baseline. Submit original to ECOG Coordinating Center along with the appropriate RECIST Disease Evaluation Form (baseline or follow-up). Keep a copy for your files.

ECOG clinical trial administrative data
Reporting Period
Data amendment
On Treatment
On Treatment Report Period (since start of treatment)
Off Treatment
Off Treatment Report Period (since registration)
Nontarget Lesions
Site Code
Method of Evaluation
Follow-Up Status of Lesion (Choose one for each lesion. Leave blank if baseline.)
Cytology Result (For Site Code 04 effusion/ascites ONLY:)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial